AnaptysBio, Inc.
NASDAQAnaptysBio enters the final days of Q3 with a crowded short book, a string of analyst target cuts, and a dense calendar of binary events starting in October. Short positioning has barely budged since the note published a week ago. Short interest remains near 19.7% of the free float, up roughly 1.3% over the past month and 0.6% on the week. The grind higher is slow but persistent…
Snapshot as of 30 Sept 2026
AnaptysBio enters the final days of Q3 with a crowded short book, a string of analyst target cuts, and a dense calendar of binary events starting in October. Short positioning has barely budged since the note published…
AnaptysBio heads into the final stretch of Q3 with an unusual split signal — nearly one-in-five shares shorted against the most bullish options reading in months. Short interest is the dominant structural feature here.…
AnaptysBio heads into the back half of June with its most striking divergence in months: options traders have turned sharply bullish while short sellers quietly add to one of biotech's larger short positions. The…
AnaptysBio enters the week in a striking tension: short interest has climbed to a meaningful 17.5% of free float while options traders have pivoted to their most bullish posture in months — a split that makes the next…
AnaptysBio enters the post-earnings session as a stock at war with itself — fresh evidence of commercial weakness on one side, a chorus of analysts lifting targets on the other. Q1 results released Tuesday evening were…
AnaptysBio reports Q1 results on May 15 with short sellers quietly adding pressure just as the stock trades near its lowest level in months. The short interest angle is the standout setup heading into this print. Bears…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ANAB — free to start on ORTEX.
Sign up for free →Open ANAB on ORTEX